PharmaKing
CompanySouth Korea
PharmaKing develops one asset, in phase 2, no development reported (oltipraz in cirrhosis). Mostly small molecule; based in South Korea.
- 1
- Asset
- Furthest stage
- Phase 2, no development reported
- 4
- Trials
- 2
- Signals
Pipeline
1Inhibits LXRα-mediated lipogenesis and activates NRF2 antioxidant responses.
Phase 2, no development reported, Small molecule, cirrhosis, liver fibrosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials4
- Signals4
- Similar companies6